We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Although prominent COVID-19 vaccine makers have argued for ramping up production to help meet global vaccine needs as an alternative to waiving intellectual property (IP) rights, several pharma companies, including the world’s biggest generics maker, have been unable to secure such manufacturing arrangements. Read More
The pharmaceutical industry has engaged in record-breaking spending on lobbying efforts in the first quarter of 2021, according to a nonpartisan lobbying research group, as Democrats continue their push for passage of drug pricing measures. Read More
Eli Lilly has partnered with UK-based MiNA Therapeutics to develop treatments using small activating RNA (saRNA) technology, a new class of drugs pioneered by MiNA. Read More
Amplyx’s Fosmanogepix is being evaluated in ongoing phase 2 trials in both intravenous and oral formulations for treatment of life-threatening fungal infections. Read More
Deliveries of the J&J vaccine, which were recently paused as the European Medicines Agency investigated the risk of blood clots, are now resuming in Europe with a blood clot warning added to the product information. Read More